PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Featured in Equity Research Report

November 15, 2021 12:46:18

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, was featured in a recent equity research report. The coverage, initiated by Maxim Group LLC, highlights MINDCURE’s efforts to set the stage to unlock value for the company. This includes work on its ongoing programs and clinical development, including synthetic ibogaine, for which it is planning a preclinical study with its research partner to initially conduct cardiac and neurological screens with data and potentially move into behavioral studies. In addition, the company plans to schedule a pre-IND meeting for its Desire Project in the first quarter of 2022 with a P2 planned for the third quarter of 2022 and has also initiated a candidate selection program for two additional pipeline compounds. Further, “For iSYTRM, MINDCURE has exceeded its initial target for the minimum viable product (‘MVP’) launch, securing 20 partner clinics (from a target of 10 by YE21). Full deployment is expected in C1Q22, with expansion to Europe by 4Q22. An additional internally developed ketamine protocol is expected to be released in C1Q22,” the report reads. “Key in 2021 for MINDCURE has been to continue to ‘block and tackle’ to best position the company in a rapidly evolving psychedelic-based medicines space. As such, while valuation has pulled back this year, the pieces should be in place to start to unlock value in MCUR/MCURF shares in 2022.”

To view the full report, visit

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.